2.27
price up icon4.13%   0.09
after-market After Hours: 2.27
loading
Iovance Biotherapeutics Inc stock is traded at $2.27, with a volume of 15.10M. It is up +4.13% in the last 24 hours and down -4.62% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$2.18
Open:
$2.2
24h Volume:
15.10M
Relative Volume:
1.02
Market Cap:
$821.41M
Revenue:
$241.53M
Net Income/Loss:
$-389.92M
P/E Ratio:
-1.8455
EPS:
-1.23
Net Cash Flow:
$-323.54M
1W Performance:
+2.71%
1M Performance:
-4.62%
6M Performance:
-20.35%
1Y Performance:
-76.65%
1-Day Range:
Value
$2.18
$2.34
1-Week Range:
Value
$2.09
$2.38
52-Week Range:
Value
$1.6385
$12.51

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
Name
Iovance Biotherapeutics Inc
Name
Phone
(650) 260-7120
Name
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Name
Employee
838
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
IOVA's Discussions on Twitter

Compare IOVA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IOVA
Iovance Biotherapeutics Inc
2.27 788.84M 241.53M -389.92M -323.54M -1.23
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.15 105.19B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
450.68 60.24B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.86 61.82B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
798.94 49.09B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
351.09 37.52B 4.56B -176.77M 225.30M -1.7177

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-15-25 Downgrade Goldman Neutral → Sell
May-16-25 Downgrade UBS Buy → Neutral
May-12-25 Downgrade Truist Buy → Hold
May-09-25 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
Oct-24-24 Initiated UBS Buy
Jul-29-24 Downgrade Piper Sandler Overweight → Neutral
Nov-20-23 Initiated Goldman Buy
Sep-18-23 Reiterated Barclays Overweight
May-30-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-27-23 Resumed Wells Fargo Equal Weight
Jan-27-23 Upgrade Piper Sandler Neutral → Overweight
Dec-09-22 Downgrade Goldman Buy → Neutral
Oct-31-22 Initiated Guggenheim Neutral
Aug-18-22 Resumed Wells Fargo Equal Weight
Jan-28-22 Upgrade Stifel Hold → Buy
Dec-07-21 Resumed Cowen Outperform
Jun-10-21 Upgrade JMP Securities Mkt Perform → Mkt Outperform
May-20-21 Downgrade Piper Sandler Overweight → Neutral
May-19-21 Downgrade JMP Securities Mkt Outperform → Mkt Perform
May-19-21 Downgrade Stifel Buy → Hold
May-03-21 Initiated Truist Buy
Apr-16-21 Initiated Goldman Buy
Mar-08-21 Upgrade H.C. Wainwright Neutral → Buy
Dec-15-20 Downgrade H.C. Wainwright Buy → Neutral
Oct-06-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-22-20 Initiated Mizuho Buy
Mar-04-20 Initiated Barclays Overweight
Feb-26-20 Reiterated H.C. Wainwright Buy
Feb-26-20 Reiterated Oppenheimer Outperform
Dec-18-19 Initiated JMP Securities Mkt Outperform
Oct-01-19 Initiated Stifel Buy
Apr-29-19 Initiated Piper Jaffray Overweight
Feb-28-19 Reiterated Chardan Capital Markets Buy
Feb-07-19 Initiated Robert W. Baird Outperform
Dec-31-18 Resumed B. Riley FBR Buy
Jul-06-18 Reiterated Chardan Capital Markets Buy
Apr-10-18 Upgrade B. Riley FBR, Inc. Neutral → Buy
Mar-13-18 Reiterated B. Riley FBR, Inc. Neutral
Feb-23-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Jan-25-18 Reiterated H.C. Wainwright Buy
Nov-01-17 Reiterated B. Riley FBR, Inc. Buy
View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

pulisher
03:08 AM

IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues - GlobeNewswire

03:08 AM
pulisher
01:15 AM

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 6.7%What's Next? - MarketBeat

01:15 AM
pulisher
Oct 06, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 4.5%Should You Sell? - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Iovance Biotherapeutics (IOVA): Examining Valuation as Share Price Momentum Stalls - Yahoo Finance

Oct 06, 2025
pulisher
Oct 06, 2025

How supply shortages influence Iovance Biotherapeutics Inc. (2LB) stock2025 Price Momentum & Growth Oriented Trade Recommendations - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Will Iovance Biotherapeutics Inc. rebound enough to break evenAnalyst Downgrade & Safe Entry Trade Signal Reports - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Why Iovance Biotherapeutics Inc. (2LB) stock fits value portfoliosChart Signals & Verified Technical Signals - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Will Iovance Biotherapeutics Inc. (2LB) stock announce special dividendMarket Sentiment Report & Weekly Top Performers Watchlists - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

What the Recent 11% Surge Means for Iovance Biotherapeutics Stock in 2025 - Sahm

Oct 05, 2025
pulisher
Oct 05, 2025

Why Iovance Biotherapeutics Inc. (2LB) stock signals breakout potentialJuly 2025 Opening Moves & Pattern Based Trade Signal System - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Oct 04, 2025
pulisher
Oct 03, 2025

Iovance Biotherapeutics (IOVA) Valuation in Focus After Recent Share Price Gains - Sahm

Oct 03, 2025
pulisher
Oct 03, 2025

How Iovance Biotherapeutics Inc. stock performs during Fed tightening cyclesShort Setup & Capital Efficient Trade Techniques - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Is Iovance Biotherapeutics Inc. (2LB) stock positioned for digital growth eraMarket Volume Summary & AI Enhanced Trading Alerts - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Analyzing Iovance Biotherapeutics Inc. with multi timeframe chartsJuly 2025 Fed Impact & Technical Buy Zone Confirmations - newser.com

Oct 02, 2025
pulisher
Oct 01, 2025

Volatility clustering patterns for Iovance Biotherapeutics Inc.Quarterly Market Review & Capital Efficiency Focused Strategies - newser.com

Oct 01, 2025
pulisher
Sep 30, 2025

Iovance Biotherapeutics Inc Stock Analysis and ForecastBull Market Opportunities & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in

Sep 30, 2025
pulisher
Sep 30, 2025

What analysts say about Iovance Biotherapeutics Inc stockMoving Average Crossovers & High Return Trading Portfolio - earlytimes.in

Sep 30, 2025
pulisher
Sep 28, 2025

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛

Sep 28, 2025
pulisher
Sep 27, 2025

Is Iovance Biotherapeutics Inc 2LB a good long term investmentStock Market Trends & Access Free Tools and Start Investing - Early Times

Sep 27, 2025
pulisher
Sep 27, 2025

Is Iovance Biotherapeutics Inc a good long term investmentCapital Gains Strategies & Free Hedging Tactics for Volatile Markets - Early Times

Sep 27, 2025
pulisher
Sep 27, 2025

Iovance Biotherapeutics Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo

Sep 27, 2025
pulisher
Sep 26, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Share Price Passes Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat

Sep 26, 2025
pulisher
Sep 25, 2025

Healthcare's Convergence Accelerates as Aging Demographics Meet Breakthrough Therapies - Baystreet.ca

Sep 25, 2025
pulisher
Sep 21, 2025

Assessing Iovance Biotherapeutics (IOVA) Valuation Following Key Strategic Updates and Growth Plans - Sahm

Sep 21, 2025
pulisher
Sep 21, 2025

Revenue Check: Can Iovance Biotherapeutics Inc deliver consistent EPS growthTrade Entry Report & AI Enhanced Execution Alerts - خودرو بانک

Sep 21, 2025
pulisher
Sep 20, 2025

Iovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will Triple - MSN

Sep 20, 2025
pulisher
Sep 20, 2025

Published on: 2025-09-21 02:39:03 - خودرو بانک

Sep 20, 2025
pulisher
Sep 20, 2025

Buy Signal: Can Iovance Biotherapeutics Inc grow without dilutionJuly 2025 Retail & AI Enhanced Execution Alerts - khodrobank.com

Sep 20, 2025
pulisher
Sep 20, 2025

Valuation Update: Will Iovance Biotherapeutics Inc benefit from AI trendsMarket Activity Recap & Weekly Return Optimization Plans - خودرو بانک

Sep 20, 2025

Iovance Biotherapeutics Inc Stock (IOVA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Iovance Biotherapeutics Inc Stock (IOVA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Puri Raj K.
Chief Regulatory Officer
Sep 02 '25
Option Exercise
0.00
5,470
0
215,324
GRAF FINCKENSTEIN FRIEDRICH
Chief Medical Officer
Sep 02 '25
Option Exercise
0.00
12,697
0
111,857
BILINSKY IGOR
Chief Operating Officer
Sep 02 '25
Option Exercise
0.00
12,306
0
105,939
Kirby Daniel Gordon
Chief Commercial Officer
Jun 05 '25
Buy
1.84
30,000
55,200
30,000
Puri Raj K.
Chief Regulatory Officer
Jun 02 '25
Option Exercise
0.00
5,469
0
212,321
Vogt Frederick G
Interim CEO & General Counsel
Jun 02 '25
Option Exercise
0.00
52,085
0
426,731
GRAF FINCKENSTEIN FRIEDRICH
Chief Medical Officer
Jun 02 '25
Option Exercise
0.00
12,695
0
105,608
BILINSKY IGOR
Chief Operating Officer
Jun 02 '25
Option Exercise
0.00
12,305
0
99,883
Bellemin Jean-Marc
Chief Financial Officer
Jun 02 '25
Option Exercise
0.00
8,789
0
64,993
Puri Raj K.
Chief Regulatory Officer
May 23 '25
Buy
1.74
5,600
9,743
206,852
$85.38
price down icon 2.05%
$23.34
price up icon 4.71%
$32.74
price up icon 0.31%
$106.28
price up icon 0.21%
$161.81
price down icon 0.31%
biotechnology ONC
$351.09
price up icon 2.77%
Cap:     |  Volume (24h):